Boston, MA – For emerging biotechnology companies poised to transition from the preclinical to the clinical stage, the selection of a Contract Research Organization (CRO) is not merely a logistical decision; it is a cornerstone of success. In an exclusive interview at the 2026 Outsourcing in Clinical Trials New England conference, Scott Sawicki, Senior Director of Strategic Sourcing and Vendor Management at Centessa Pharmaceuticals, offered invaluable insights into how these nascent drug developers can navigate the complex landscape of clinical outsourcing and forge partnerships that drive their programs forward.
Sawicki, whose extensive experience spans major pharmaceutical corporations, innovative biotech ventures, and the CRO sector itself, provided a candid assessment of the opportunities and potential pitfalls that await companies embarking on their first clinical trials. His perspective, honed by a deep understanding of the entire drug development lifecycle, is particularly pertinent given Centessa Pharmaceuticals’ recent acquisition by Eli Lilly in June 2026, a move that underscores the company’s strategic growth and potential within the broader pharmaceutical ecosystem.
The conversation, held with Clinical Trials Arena reporter Frankie Fattorini during the conference in Boston on October 27-28, 2026, delved into the critical considerations for early-stage drug developers when identifying and engaging with CRO partners. Sawicki emphasized that a well-chosen CRO can act as an extension of the biotech’s own team, providing essential expertise, infrastructure, and operational efficiency that are often beyond the reach of smaller, resource-constrained organizations. Conversely, a misaligned partnership can lead to costly delays, compromised data integrity, and ultimately, a jeopardized drug candidate.
The Crucial Juncture: Why CROs Matter for Early-Stage Biotechs
The transition from laboratory discovery to human clinical trials represents a significant inflection point for any biotechnology company. It signifies a shift from the controlled environment of preclinical research to the dynamic and complex realities of patient care, regulatory oversight, and intricate logistical coordination. For many small biotechs, this leap necessitates reliance on external expertise and resources, making the CRO a vital enabler of progress.
"When you’re a small biotech, particularly one that has just successfully navigated the preclinical hurdles and is gearing up for its first Phase I or even a First-in-Human study, you’re often operating with a lean team," Sawicki explained. "You might have brilliant scientists and a promising molecule, but the operational infrastructure, the deep regulatory knowledge for conducting trials in multiple geographies, the site relationships, the data management capabilities – these are all areas where a CRO can provide immediate and indispensable value."
He elaborated that the primary driver for engaging a CRO at this stage is often the need to access specialized expertise that is not core to the biotech’s internal capabilities. This can range from regulatory affairs and quality assurance to clinical operations, data management, biostatistics, and pharmacovigilance. Without these foundational elements in place, a biotech risks faltering at the very threshold of clinical validation.
Navigating the Vendor Landscape: Sawicki’s Strategic Framework
Sawicki outlined a multi-faceted approach for biotechs seeking to identify the ideal CRO partner, emphasizing that the process should be both strategic and meticulous. He cautioned against a purely cost-driven selection, stressing that value, expertise, and cultural fit are equally, if not more, important.
1. Defining Core Needs and Objectives:
"Before you even start looking at CROs, you need to have absolute clarity on what you need them to do," Sawicki advised. "What are your specific clinical development goals for this trial? What are the key performance indicators for success? Are you looking for full-service support, or do you have certain capabilities in-house and need to outsource specific functions? Understanding your own needs intimately is the first step to finding a partner who can meet them."
This involves a thorough assessment of the biotech’s current capabilities, identifying any gaps in expertise, infrastructure, or personnel. It also means clearly defining the scope of work, the desired timelines, and the budget constraints. For early-stage biotechs, this might involve designing the study protocol, selecting clinical sites, managing patient recruitment, collecting and analyzing data, and ensuring regulatory compliance.
2. The Importance of CRO Specialization and Experience:
Sawicki underscored the significance of a CRO’s track record and therapeutic area expertise. "Not all CROs are created equal," he stated. "Some excel in oncology, others in rare diseases, and some have broad capabilities across multiple therapeutic areas. For an emerging biotech, it’s crucial to find a CRO that has demonstrable experience with the specific disease indication you’re targeting, and ideally, has a history of successfully running the types of trials you intend to conduct."
This specialization extends beyond therapeutic areas to encompass the specific phase of development. A CRO with extensive experience in Phase III pivotal trials might not be the best fit for a Phase I first-in-human study, which requires a different set of skills and regulatory considerations. Sawicki recommended looking for CROs that have a proven ability to manage early-phase studies, demonstrating a nuanced understanding of dose escalation, safety monitoring, and pharmacokinetic/pharmacodynamic profiling.
3. Beyond the Contract: Cultural Fit and Communication:
"A strong working relationship is built on more than just a contract," Sawicki emphasized. "You need to find a CRO whose culture aligns with yours. Are they agile and responsive? Do they have a proactive approach to problem-solving? How is their communication style? When you’re in the trenches of a clinical trial, especially when facing unexpected challenges, effective and transparent communication with your CRO partner is paramount."
He highlighted the importance of a dedicated project management team from the CRO, individuals who are not only operationally skilled but also adept at fostering collaboration and managing expectations. For small biotechs, the ability to establish a close, collaborative relationship with their CRO counterparts can be a significant advantage, ensuring that the project stays on track and that any issues are addressed swiftly and efficiently.
4. Due Diligence and Risk Assessment:
Sawicki strongly advocated for a rigorous due diligence process, going beyond initial presentations and proposal reviews. "You need to kick the tires, so to speak," he said. "Ask for references from other companies, preferably those of similar size and stage, who have worked with the CRO. Understand their quality management systems, their data security protocols, and their contingency plans for unforeseen events. What are their regulatory inspection histories? A thorough risk assessment upfront can save a lot of heartache down the line."
This due diligence should also extend to understanding the CRO’s financial stability and business continuity plans. For a small biotech, an over-reliance on a financially unstable CRO could pose a significant risk to their program’s continuity.
The Centessa Advantage: A Blend of Big Pharma Acumen and Biotech Agility
Sawicki’s perspective is particularly insightful given Centessa Pharmaceuticals’ recent trajectory. The acquisition by Eli Lilly in June 2026 brought Centessa into the fold of one of the world’s leading pharmaceutical giants, a move that often signifies a maturation and scaling of operations. However, Centessa itself was built on the premise of fostering a portfolio of innovative, early-stage drug candidates, often incubated from academic discoveries. This unique blend of big pharma resources and an agile, biotech-centric approach likely informs Sawicki’s pragmatic yet forward-looking advice.
"My experience has given me a 360-degree view of the drug development ecosystem," Sawicki noted. "I’ve seen the immense capabilities of large pharmaceutical organizations, but I’ve also experienced the agility and focused innovation that defines successful biotech companies. And critically, I’ve worked within CROs, understanding their operational complexities and their value proposition. This allows me to appreciate the specific challenges and opportunities faced by an emerging biotech looking to partner with a CRO."
He suggested that biotechs should seek CROs that can offer a similar balance – the operational robustness and regulatory expertise of larger organizations, coupled with the flexibility and personalized attention often found in smaller, more specialized CROs.
Chronology of a CRO Engagement: From Selection to Execution
The process of engaging a CRO for a biotech’s first clinical trial typically follows a defined, albeit often iterative, pathway.
- Initial Scoping and Needs Assessment: The biotech company meticulously defines its project requirements, therapeutic area, phase of development, desired geographic reach, and budget. This internal exercise is foundational.
- Longlist and Shortlist Development: Based on initial research, industry recommendations, and therapeutic area expertise, the biotech creates a longlist of potential CROs. This is then narrowed down to a shortlist based on preliminary evaluations of their capabilities and alignment with the biotech’s needs.
- Request for Proposal (RFP) Process: Detailed RFPs are issued to shortlisted CROs, outlining the specific scope of work, timelines, and data requirements. This phase allows for a comparative analysis of proposals.
- Vendor Presentations and Site Visits: The top contenders present their proposals and capabilities to the biotech team. In some cases, visits to the CRO’s facilities and key operational centers may be arranged to assess their infrastructure and quality systems firsthand.
- Due Diligence and Reference Checks: Rigorous due diligence, including reference checks with past clients and examination of regulatory histories, is conducted.
- Contract Negotiation: Once a preferred partner is identified, contract negotiations commence, covering all aspects of the agreement, including budget, timelines, deliverables, intellectual property, and termination clauses.
- Project Kick-off and Execution: Upon contract finalization, a formal project kick-off meeting is held, establishing the project team, communication protocols, and key performance indicators. The CRO then assumes responsibility for the outsourced activities, with ongoing oversight and management from the biotech.
- Ongoing Monitoring and Performance Review: Throughout the trial, the biotech company actively monitors the CRO’s performance against agreed-upon metrics. Regular review meetings are held to address any issues, make necessary adjustments, and ensure the project remains on track.
Sawicki emphasized that this entire process, from initial outreach to ongoing project management, requires dedicated internal resources within the biotech company. "You can’t just hand over the reins and walk away," he cautioned. "Even with a great CRO, you need internal expertise to oversee the relationship, ensure alignment, and make critical strategic decisions. Your internal team needs to understand the clinical trial process, regulatory requirements, and how to effectively manage external vendors."
Supporting Data and Industry Trends
The increasing reliance on CROs is a well-documented trend in the pharmaceutical and biotechnology industries. Data from various market research reports consistently highlight the growth of the global CRO market, driven by the rising costs of drug development, the increasing complexity of clinical trials, and the growing demand for specialized expertise.
- Market Growth: The global CRO market is projected to continue its upward trajectory, with analysts predicting significant compound annual growth rates (CAGRs) over the next decade. This expansion is fueled by the continuous pipeline of drug candidates requiring clinical validation and the strategic outsourcing decisions made by pharmaceutical and biotech companies of all sizes.
- Therapeutic Area Focus: Oncology, immunology, and neurology remain dominant therapeutic areas in clinical research, and consequently, CROs with specialized expertise in these fields are in high demand.
- Geographic Diversification: While North America and Europe remain major hubs for clinical trials, there is a growing trend towards conducting trials in emerging markets, driven by factors such as faster patient recruitment and lower costs. CROs with a global footprint and experience in diverse regulatory environments are therefore highly sought after.
- Technological Advancements: The integration of technology, including artificial intelligence (AI), machine learning (ML), and decentralized clinical trial (DCT) solutions, is transforming the CRO landscape. Biotechs are increasingly looking for CRO partners who can leverage these technologies to improve efficiency, enhance data quality, and streamline patient engagement.
Sawicki acknowledged these trends, noting that "the CRO landscape is constantly evolving. Companies that are investing in new technologies, adapting to new regulatory frameworks, and demonstrating a commitment to innovation are the ones that will be most attractive to emerging biotechs."
Official Responses and Regulatory Considerations
The regulatory landscape for clinical trials is stringent and constantly evolving, overseen by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Sawicki stressed that any CRO engaged must possess a deep understanding of these regulatory requirements and a proven track record of compliance.
"Regulatory compliance is non-negotiable," he stated unequivocally. "Your CRO must have robust quality management systems in place, adhere to Good Clinical Practice (GCP) guidelines, and be prepared for regulatory inspections. They should also be adept at navigating the complexities of submissions and approvals in different regions."
He further elaborated that CROs play a crucial role in ensuring that clinical trial data is collected, managed, and reported in a manner that meets regulatory standards. This includes data integrity, data security, and the timely submission of required documentation.
Implications for the Future of Drug Development
The strategic engagement of CROs by emerging biotechs has profound implications for the future of drug development. By enabling smaller companies to access the resources and expertise necessary to conduct clinical trials, CROs act as crucial accelerators of innovation.
- Democratization of Drug Development: The ability to effectively outsource critical functions allows a broader range of innovative ideas to be tested and brought to patients. This democratizes the drug development process, reducing the barrier to entry for smaller, agile organizations.
- Faster Time to Market: Efficient CRO partnerships can significantly shorten the timeline from discovery to market, bringing potentially life-saving therapies to patients more quickly.
- Focus on Core Competencies: By offloading operational and logistical burdens to CROs, biotechs can free up their internal resources to focus on their core competencies: scientific innovation, drug discovery, and strategic decision-making.
- Increased Collaboration and Knowledge Sharing: The close working relationships forged between biotechs and CROs foster knowledge sharing and collaboration across the industry, driving continuous improvement in clinical trial methodologies and best practices.
Sawicki concluded with a forward-looking statement, emphasizing the symbiotic relationship between biotechs and CROs. "As the drug development landscape continues to become more complex and specialized, the role of the CRO will only become more critical," he said. "For emerging biotechs, selecting the right CRO partner is not just about outsourcing a task; it’s about building a strategic alliance that can propel their innovations from the lab bench to the patients who need them. It requires careful consideration, rigorous due diligence, and a commitment to building strong, collaborative relationships."
The insights shared by Scott Sawicki at the Outsourcing in Clinical Trials New England conference provide a vital roadmap for emerging biotechs embarking on their clinical journey. By understanding their needs, conducting thorough due diligence, and prioritizing expertise and cultural alignment, these companies can harness the power of CRO partnerships to navigate the complexities of clinical development and accelerate the delivery of groundbreaking therapies to the world.
To delve deeper into discussions on customizing clinical trials without increasing patient burden, explore more podcasts from the GlobalData Media Healthcare team available on Spotify here. GlobalData is the parent company of Clinical Trials Arena.
About the Author
